List of Small Molecule Pharmaceuticals Companies in Delaware - 13

Adesis Inc. is a premier chemistry solution company backed by expert chemists and partnering with biotech and pharma industries to accelerate their research and manufacturing goals. Through the years, we've retained our original culture anchored in ethics, integrity, values, family, transparency, speed, safety and trust. We are one of the few companies that can turn a difficult whiteboard chemistry concept into a physical product. We specialize in organic and organometallic synthesis and deliver organic chemistry services in three areas: early-stage research, scale-up and development, and specialty manufacturing. Our turnaround times are recognized as among the fastest in the industry – a direct result of minimizing red tape, maximizing lab time and quick, efficient decision-making. When clients say ‘let's begin,' we've already started. The companion to this remarkable speed is our commitment to safety. The Adesis Facility Safety Program is designed to constantly raise the level of awareness of safe work practices. Our vigilance extends to the protection of client patents and intellectual property. Backed by the effective use of systems, security and formalized processes, client confidentiality is always a priority. We pride ourselves on our chemists being respected for their brilliance and enthusiasm to collaborate and adapt. If a client needs to shift, we pivot quickly to provide the necessary facilities and specialist brainpower to address any challenge and keep the project moving. The compounds we develop for clients have found use in life-enhancing oncology, anti-infective, animal treatment, central nervous system, immunotherapy, therapeutic, ophthalmic, biomarkers, skin care, catalysts and other applications. Reliably and safely solving the toughest chemistry problems in partnership with its clients is the core purpose of Adesis. Trusted collaboration with exceptional chemistry teams. In Adesis hands, the science is not complicated.

Founded in 2002, ANP Technologies, Inc. is an emerging nanobiotechnology company with a major focus on design, development, and marketing of innovative technologies. ANP Technologies, Inc. is a nanobiotechnology company with cutting-edge technology platforms focused on: • Specialty CRO for biological drug R&D • Biodefense and homeland security • Home/point-of-care diagnostic systems • Nanoencapsulation and targeted drug delivery and therapy

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company’s product candidates, AL101 and AL102, were licensed into Ayala from Bristol Myers Squibb. Our lead product candidate AL101 is currently in Phase 2 clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma, for patients bearing Notch-activating mutations. Our second product candidate AL102 is being developed for the treatment of desmoid tumors. In addition, we are collaborating with Novartis to develop AL102 for the treatment of multiple myeloma in combination with Novartis’ B-cell maturation antigen (BCMA) targeting therapies. The company is based in the US and Israel.

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together. BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. Historical successful investments include divestment of Dezima Pharma to Amgen for up to USD 1.55 billion in total deal value and in Acerta Pharma for up to USD 7 billion with a guaranteed payment of USD 4 billion. Both companies were co-founded by BGV in 2012 and 2013 respectively. The Acerta Pharma sale was the largest exit ever of a privately held European biotech company. BGV is based in Naarden, The Netherlands, and closely collaborates with Forbion.

EOLO PHARMA is a pharmaceutical company that focuses on drug discovery and developing novel molecules for the treatment of obesity.

Foresee Pharmaceuticals is a Taiwan and US-based biopharmaceutical company listed on the Taipei Stock Exchange. The company engages in the pharmaceutical sector and focuses on developing innovative drugs for various medical conditions such as prostate cancer, asthma, and COPD. Foresee Pharmaceuticals has a diverse set of clinical and development candidates with distinct profiles and patents.

Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. We are committed to the relentless pursuit of science that can improve the lives of patients. Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity. Headquartered in Wilmington, Delaware, Incyte has more than 1,700 employees and operations in North America, Europe and Asia. We are proud to have been recently recognized by Forbes as one of the World’s Most Innovative Companies. Additionally, Incyte has consecutively been named a Top Employer by Science Magazine, placing #2 on the 2020 list. For more information about Incyte, please visit our corporate website at www.incyte.com and follow us on Twitter: www.twitter.com/incyte. See our Community Guidelines: http://bit.ly/2sV0H5W.

Neurolixis Inc. is a biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system diseases including movement disorders, autism spectrum disorders, depression and pain.

We create innovative, life-saving treatments and bring hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. We apply our unique clinical and scientific expertise, partnered with leading medical experts, to develop known molecules for medical conditions with no indicated therapies. NRx believes in a world where scientific advancement makes untreatable diseases treatable. We are committed to bringing new treatments and hope for people with chronic medical conditions so they may live full lives.

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.

Progentos Therapeutics is a biotech company focused on developing treatments for multiple sclerosis and other neuropsychiatric disorders. The company has raised $65 million in Series A financing and will have operations in Watertown, MA, USA and Naarden, The Netherlands.

Synnovation Therapeutics is a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets. We are dedicated to the discovery and development of best-in-class therapeutics that can improve the lives of people living with cancer. Leveraging deep expertise in cancer biology and a world class medicinal chemistry team, we are building a diverse pipeline of novel small molecule targeted therapies. Our mission is to efficiently advance these agents into clinical trials with the goal of transforming cancer care through patient-focused precision medicine.

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 12,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $4.5 billion.